Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Perfluorocarbon oxygen carrier - Tenax Therapeutics

Drug Profile

Perfluorocarbon oxygen carrier - Tenax Therapeutics

Alternative Names: ABL-101; Oxycyte; Wundecyte

Latest Information Update: 20 Jan 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Synthetic Blood International
  • Developer Aurum Biosciences; Naval Medical Research Center; Oxygen Biotherapeutics
  • Class Cyclohexanes; Fluorocarbons; Small molecules
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Air embolism; Decompression sickness; Skin disorders; Stroke; Wounds
  • Discontinued Brain injuries; Hypoxia; Poisoning; Sickle cell anaemia; Spinal cord injuries

Most Recent Events

  • 13 Mar 2018 Aurum Biosciences plans the POST-IT phase II trial for Stroke in March 2018 , (NCT03463551)
  • 19 Sep 2014 Oxygen Biotherapeutics is now called Tenax Therapeutics
  • 11 Sep 2014 Discontinued - Phase-II for Brain injuries in Israel (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top